We are tightly focused in the oncology pharmaceutical arena. There's a big unmet need for new anti-cancer drugs. The challenge is in developing new effective agents, and that's where we've built our core competency to date. Plus, we've got a robust pipeline to take us into the next phase of the company. As you know, it's a very capital-intensive industry.
Drug development is expensive.
I think if we were offered what our board and shareholders believed was a good value for the company, we would give it full consideration. We are building a pharmaceutical pipeline that could be attractive to the major pharma companies, although that is not our objective. When you discussed building a commercialization expertise within the company, the obvious choice there is to buy or build. You seem to have the financial wherewithal to buy or build. Over the last roughly 12 months we've acquired two subsidiaries of other companies as well as a private company in Boston with a great technology platform.